Kornimate/medical-research-clean huggingface dataset:
the utility of osteopathic manipulative medicine in weaning patients from the ventilator pilot trial

Conditions: Respiratory Failure; Osteopathy in Diseases Classified Elsewhere

Summary: the objectives of this research are to determine the treatment effect size of omm to wean patients off of the ventilator, determine the number of patients needed for a larger study (power), determine the willingness of patients/poas to be recruited, identify the correct dosing of omm and whether there are concerns for the safety of treatment, and determine whether the hypothesis is feasible for a larger study. the primary outcome measure is the duration of time until a subject is weaned off of mechanical ventilation using osteopathic manipulative medicine (omm). the secondary outcome measures (see the next section for further explanation) are to determine if omm affects changes in morbidity and mortality, such as vbg/abg, nif, rsbi, p 0.1, fio2, peep, mental status, hemodynamic stability (blood pressure), spontaneous tv, reintubation after extubation, and death.


Eligibility criteria:
inclusion criteria: 1. acute respiratory failure (hypoxic, hypercapnic, or neuromuscular) 2. not making satisfactory progress with weaning after being on the ventilator for more than 48 hours 3. clinical stability for pressure support trial with ventilator to monitor ventilation progression 4. pulmonology must be following the patient for standardized ventilator management approach and interventions as needed 5. medical power of attorney (poa) or legally authorized representative (lar) who is able to consent subject for trial enrollment and treatment 6. patients who were not referred to the omm service exclusion criteria: 1. age less than 18 years old or more than 85 years old 2. bmi\>60 3. moderate/severe neurological disease with expectation of non-progression off the ventilator or poor quality of life predicted (including end-stage dementia with the expectation of non-progression off ventilator, multiple sclerosis, als, anoxic brain injury, etc) 4. status epilepticus or eeg result pending 5. post-arrest hypothermia protocol 6. acute stroke 7. acute rib fractures preventing the implementation of the treatment protocol 8. acute spinal injury preventing the implementation of the treatment protocol 9. recent head injury requiring close clinical monitoring 10. ejection fraction less than 15% 11. pleural effusion requiring procedural intervention or inhibiting ventilator progress 12. pericardial effusion or tamponade requiring procedural intervention or inhibiting ventilator progress 13. acls/cardiac arrest within the past 72 hours 14. confirmed opioid overdose with positive urine drug screen and response to naloxone 15. patients who were referred to the omm service
combination therapy of diet with biologicals for crohn's disease: the oats study

Conditions: Crohn Disease; Inflammatory Bowel Diseases; Diet, Healthy

Summary: this study is a randomised open label study, comparing the fit diet with standard diet in patients with crohn's disease treated with biologic therapy.


Eligibility criteria:
inclusion criteria: * adult patients (18-80 years) * active inflammation of terminal ileum and/or colon with a simple endoscopic score for crohn's disease (ses-cd) greater than 5 (or greater than 3 for patients with isolated ileitis), * patient reported outcome 2 (pro2 - 7 day average daily stool frequency x 2 + 7 day average daily abdominal pain score x 5) \> 8, * faecal calprotectin above 250 µg/g. exclusion criteria: * abcess, * bowel resection within 6 months before enrolment, * ostomy, * short-bowel syndrome, * clinically significant stricture that could require surgery, * pregnant, * lactating woman or desire to become pregnant during the study, * unwilling or unable to follow the study diet.
effect of calcium chloride on recovery from neuromuscular blockade

Conditions: Residual Neuromuscular Blockade

Summary: the purpose of this study is to evaluate the effect of calcium chloride against residual neuromuscular blockade at the end of general anesthesia

during general anesthesia, neuromuscular blocking agent is administered to facilitate endotracheal intubation and the view of operative field. the neuromuscular blockade should be reversed at the end of anesthesia to recover spontaneous breathing of the patient. residual neuromuscular blockade (rnmb) is defined as train of-four ratio \< 0.9. rnmb is a risk factor for postoperative pulmonary complication and increases postoperative mortality. neostigmine is acetylcholinesterase inhibitor routinely used at the end of anesthesia to prevent rnmb. a meta-analysis, however, showed that 40 percent of patients who received intermediate-acting neuromuscular blocking agent during anesthesia showed rnmb in pacu. calcium triggers the release of acetylcholine from the motor nerve terminal and enhances excitation-contraction coupling in muscle. increasing calcium concentrations decreased the sensitivity to dtc and pancuronium in an animal muscle-nerve model. the effect of calcium chloride on residual neuromuscular blockade is not studied yet. the purpose of this study is to evaluate the effect of calcium chloride on residual neuromuscular blockade at the end of general anesthesia

Eligibility criteria:
inclusion criteria: * 18-65 yr * body mass index 15.0-25.0 kg/m2 * american society of anesthesiologists physical status i-iii * scheduled for elective surgery with an expected duration of more than 60 min under general anesthesia with endotracheal intubation exclusion criteria: * suspected difficulty airway * bronchial asthma, chronic obstructive pulmonary disease * neuromuscular disease * hepatic or renal dysfunction. * taking medications that might influence the effect of neuromuscular blocking agents * allergy to the medication that used in this trial * pregnant, or breastfeeding state * suspected malignant hyperthermia * contraindication to the medication that used in this trial * hypercalcemia

Keywords: neuromuscular blockade reversal tof ratio calcium chloride
a study to assess the safety and effectiveness of darunavir for treating human immunodeficiency virus-type i (hiv-1) infection in filipino patients

Conditions: Human Immunodeficiency Virus-Type 1

Summary: the purpose of this study is to assess the safety and effectiveness of darunavir for the treatment human immunodeficiency virus-type i (hiv-1) infection among filipino adults.

this is an open-label (all people know the identity of the intervention), multi-center (study conducted at multiple sites), uncontrolled (all the patients receiving darunavir) clinical and observational study (study in which the investigators/physicians observe the patients and measure their outcomes) to evaluate the safety and effectiveness of darunavir for the treatment human immunodeficiency virus-type 1 (hiv-1) infection among adult filipino patients. the study will enroll 10 percentage of patient who would use the product, as a requirement of the philippine food and drug administration (fda). patients will be monitored from baseline and every 4 weeks thereafter for a period of 24 weeks. safety evaluations for adverse events, clinical laboratory tests, physical examination, concomitant medications, and co-morbid conditions will be monitored throughout the study. the duration of treatment will be for 24 weeks and the total study will be conducted for 3 years.

Eligibility criteria:
inclusion criteria: * patients who are diagnosed with human immunodeficiency virus-type 1 (hiv-1), and who are eligible for darunavir (in combination with ritonavir) treatment. these may be either: treatment-naive adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions; or treatment-experienced adult patients with at least one darunavir resistance associated substitution exclusion criteria: * known hypersensitivity to darunavir/ritonavir or to any of the components of the two agent preparations * pregnant or breastfeeding females * agrees to protocol-defined use of effective contraception * patients taking medication that are highly dependent on cytochrome p450 3a4 for clearance and for which initial concentrations are associated with serious and/or life threatening events * patients with severe hepatic impairment * history of allergy to sulfa containing drugs or molecules * patients currently receiving alfuzosin, dihydroergotamine, ergonovine, ergotamine, methylergonavine, cisapride, pimozide, midazolam, triazolam, st. john's wort (hypericum perforatum), lovastatin, simvastatin, rifampin and sildenafil

Keywords: human immunodeficiency virus-type 1 hiv-1 tmc114 darunavir ritonavir filipino
clinical data collection on perceval s sutureless prosthetic aortic valve in the chinese population

Conditions: Aortic Valve Disease

Summary: the objective of the study is to evaluate the safety information on the perceval s sutureless prosthetic heart valve after the implantation for aortic valve disease. the study is designed as a post-market, observational, non-interventional retrospective and prospective registry.

in order to monitor the ongoing safety of the perceval s as part of regulatory requirements, the study aims to retrospectively collect safety outcomes and performance data in patients with aortic valve disease implanted with perceval s since 2022. the data will be used for regulatory purposes, to support the re-certification of the valve in the chinese market. serious adverse events (saes) such as valve-related death, structural valve deterioration, cerebral thromboembolism, stroke, transient ischemic attack, non-cerebral thromboembolism, major bleeding, re-operation will be studied to describe the safety profile of the valve. hemodynamic data from site reported echocardiography finding (mean gradient, peak gradient, effective orifice area, effective orifice area indexed, incidence and degree of pvl and central leak) at hospital discharge will also be evaluated. data of approximately 80 subjects will be collected in four clinical sites in china.

Eligibility criteria:
inclusion criteria: 1. subject who has been implanted with perceval s sutureless aortic heart valve 2. subject (legal representative or family member) who has signed the approved informed consent or would provide verbal informed consent/ signed and dated informed consent, and available medical information exclusion criteria: 1. subject (legal representative or family member) who do not provide consent to the data collection
research on early prediction model of ischemic cerebrovascular disease based on artificial intelligence technology.

Conditions: Ischemic Cerebrovascular Disease; Artificial Intelligence; Prediction Model

Summary: establish an artificial intelligence clinical decision support system for patients with carotid/vertebral artery cerebrovascular stenosis, early identification of patients who may have cerebral infarction. with the support of this project, it is expected that a secondary prevention clinical decision support system for chronic stroke will be established, which is likely to become an important auxiliary tool for the management of cerebrovascular diseases in the future.

stroke is a disease with a high mortality rate and incidence rate, and it is one of the main reasons for high medical expenses. ischemic stroke accounts for approximately 85% of all subtypes of stroke. carotid artery and vertebral artery stenosis are definite and intervenable risk factors for ischemic stroke. however, the selection of clinical intervention timing and methods for patients with cerebrovascular stenosis is limited to the rate of carotid/vertebral artery stenosis and the symptoms of the patients. cerebral infarction caused by carotid/vertebral artery stenosis often leads to irreparable neurological deficits. currently, there is a lack of comprehensive evaluation methods for the severity of ischemic cerebrovascular diseases such as carotid/vertebral artery stenosis, and even less a clinical decision-making system that can predict the progression of the disease. this project intends to take the demographic data and clinical information of patients with cerebrovascular stenosis from multiple centers and ethnic groups as the entry point, combine the multidisciplinary advantages of imaging, ultrasound, clinical medicine and computer science, and use artificial intelligence technology to construct a model for predicting the disease progression and the probability of adverse cardiovascular events such as stroke in patients with cerebrovascular stenosis. based on this, the investigators' hospital intends to develop a set of secondary prevention management tools and clinical decision support systems for ischemic cerebrovascular diseases.

Eligibility criteria:
inclusion criteria: patients undergoing vascular (carotid/vertebral artery) b-ultrasound exclusion criteria: patients with missing clinical data such as medical history, cerebrovascular ultrasound results and biochemical data
comparison of sit-to-stand test with six-minute walk test in bronchiectasis and healthy children

Conditions: Bronchiectasis

Summary: children with bronchiectasis and age-matched healthy controls will be evaluated with sit-to-stand test and six-minute walk test and utilization of stst in determining functional capacity will be investigated.

bronchiectasis (be) is a chronic condition which is characterized by the permanent abnormal widening of the bronchi as a result of repetitive airway infections and inflammation. disabling cough and shortness of breath, excess mucus production, progressive airway obstruction and loss of skeletal muscle mass are the primary factors that impairs exercise tolerance in be patients. imaging modalities and pulmonary function test are insufficient to determine disease burden or the prognosis thus it is stated that exercise tolerance and quality of life should also be evaluated in these patients. exercise tolerance can be evaluated using cardiopulmonary exercise test by directly measuring oxygen consumption but the field tests such as six-minute walk test (6mwt), shuttle walk test or stair climbing tests also provides reliable data on exercise tolerance by measuring functional capacity. among field tests, 6mwt is the most commonly used test for evaluating functional capacity in cardiopulmonary patients. although 6mwt is easy to apply and does not require any special equipment, it still requires a 30-m long corridor and a total testing time of approx. 20 minutes considering the pre- and post-test resting periods which may impair its feasibility in some clinical settings. sit-to-stand test (stst) is firstly developed for older population to measure mobility related function and physical performance. today, it is widely used in various populations including cardiopulmonary diseases such as cystic fibrosis, chronic obstructive pulmonary disease and heart failure. the investigator's aim in this study is to investigate whether stst is utilizable for evaluating functional capacity in children with be.

Eligibility criteria:
inclusion criteria: * diagnosis of non-cystic fibrosis bronchiectasis exclusion criteria: * hospitalization history in past month * diagnosis of other chronic pediatric diseases which may impair exercise tolerance such as cerebral palsy or neuromuscular disease * candidates for lung transplantation or history of lung transplantation

Keywords: bronchiectasis exercise capacity six-minute walk test sit-to-stand test
validity and reliability of the upper extremity star balance test in amateur league american football players

Conditions: Athletic Injuries

Summary: american football is a team activity that calls for many difficult qualities, including speed, endurance, speed, strength, and quickness. it is getting more and more popular among professional and amateur players, particularly in our nation.

balance is defined as maintaining posture and postural continuity throughout a movement, despite a changing environment or condition while the body is in motion. however, the upper extremity star balancing test offers information on only three access elements and the possible dangers may not be thoroughly assessed. as a more thorough upper extremity dynamic balance test, the upper extremity star balance test can provide data in eight directions of physicians and physiotherapists and coaches.

Eligibility criteria:
inclusion criteria: * male individuals between the ages of 18-25 * being an american football player * regular attendance at training sessions exclusion criteria: * known neurological disorder * serious orthopedic disorders that prevent exercise * cognitive impairment

Keywords: balance
a study of chenodeoxycholic acid (cdca) in newly diagnosed participants with cerebrotendinous xanthomatosis (ctx)

Conditions: Cerebrotendinous Xanthomatoses

Summary: this study is designed to demonstrate the beneficial effect of cdca in the treatment of ctx-associated diarrhea in approximately 10 participants aged 2-75 years old with newly diagnosed ctx or suspected ctx who have never received treatment with cdca.


Eligibility criteria:
inclusion criteria: * signed informed consent form (or assent form as appliable) * aged from 2 to 75 years old * has a new or suspected diagnosis of ctx as defined by an elevated plasma cholestanol concentration (\>10 mg/l/\>25.7 μmol/l) in conjunction with a clinical presentation consistent with the diseased as assessed by the investigator * has never received treatment with cdca * has never received treatment with other bile acid products exclusion criteria: * any medical condition that, in the opinion of the investigator, precludes the participant's participation in the study * presence of known hepatocyte dysfunction or bile ductal abnormalities such as intrahepatic cholestasis, primary biliary cirrhosis or sclerosing cholangitis * inability to adhere to treatment and visit schedule * female participants who are pregnant * female participants who are breast feeding * female participants who are using estrogen-containing compounds and cannot/will not discontinue them for the duration of the study * female participants of childbearing potential who are not using locally approved birth control method(s) or double barrier contraception (ie, condom and diaphragm, condom or diaphragm and spermicidal gel or foam) * taking any of the following medications: bile acid products; inhibitors of bile acid transporters; bile acid binding resins; aluminum-based antacids; coumarin and its derivatives; cholestyramine; ciclosporin; sirolimus; or phenobarbital
the efficacy and safety of huaiqihuang granule in children with chronic primary immune thrombocytopenia

Conditions: Immune Thrombocytopenia

Summary: this is a multisite, double-blind, randomized, placebo-controlled, and parallel study designed to evaluate the clinical efficacy and safety of huaiqihuang granule for treatment to children with chronic primary immune thrombocytopenia (qi yin deficiency).

the randomized clinical trial included subjects (n =216) will be randomly divided into experimental (n = 162) and control groups (n =54) according to a random number table. patients in the experimental group will receive huaiqihuang granule . patients in the control group will receive placebo a placebo-controlled designed is used for this study. to minimize the risks, treatment stopping rules and subsequent measures are established for subjects whose disease under study become worsening during the study. subjects receiving placebo treatment will switch to investigational drug after week 24 to reduce the risk of lack of efficacy by placebo. the primary outcome measures is proportion of patients whose hemorrhage has improved (clinical effective rate).

Eligibility criteria:
inclusion criteria: 1. male or female, aged between 1 and 14 years (inclusive) ; 2. is diagnosed as immune thrombocytopenia according to the criteria of icd-10, i.e., platelet \< 100×109/l for at least two hematology tests with normal blood cell morphology; skin petechia, ecchymosis and (or) the clinical manifestations of mucosa and visceral hemorrhage; no splenomegaly; exclusion of other secondary thrombocytopenia, such as aplastic leukemia, aplastic anemia characterized by thrombocytopenia as the first hematologic abnormality, hereditary thrombocytopenia, thrombocytopenia secondary to other autoimmune diseases, infections or drugs etc... 3. meet the diagnosis criteria for qi yin deficiency in traditional chinese medicine; 4. time since initial diagnosis of itp until randomization is at least 12 month, i.e., course of disease ≥1 year; 5. values of prothrombin time (pt/inr) and activated partial thromboplastin time (aptt) are within 1.2 times of normal reference range; 6. values of biochemistry parameters including creatinine, alt, ast, glucose, total bilirubin are less than 1.2 time of the corresponding upper limit of normal range; 7. has signed and dated the informed consent in volunteer by the subject and the subject's legal guardian(s) (for subject who is less than 8 years old, the informed consent will be signed and dated by the subject's legal guardian(s) in volunteer). exclusion criteria: 1. is diagnosed as congenital thrombocytopenia; 2. is diagnosed as secondary thrombocytopenia; 3. is diagnosed as non-immune thrombocytopenia; 4. has medical history of diabetes; 5. in the judgement of investigator, the subject is not appropriate to participate in this study.

Keywords: huaiqihuang granule immune thrombocytopenia randomized double-blind placebo-controlled,
incentive spirometry prehabilitation study

Conditions: Pulmonary Disease

Summary: postoperative pulmonary complications (ppcs) are the most common complication following thoracic surgery. ppcs are associated with prolonged hospital stay, increased morbidity, mortality, icu admission, and healthcare costs (azhar, 2015). current preoperative optimization in this patient group includes smoking cessation and management of chronic obstructive pulmonary disease with inhaled bronchodilators and inhaled steroids as indicated. there have been studies using preoperative incentive spirometry in patients undergoing laparotomy with conflicting results, but scant data on its use in patients undergoing one-lung ventilation (tyson, et al., 2015; cattano, et al., 2010). a study from 2013 investigated the effectiveness of incentive spirometry in patients following thoracotomy and found conflicting results, without significant improvement in lung function or reduction in ppcs, but a larger difference in frequency of ppc was noted, indicating possible benefit to intervention and a need for further study (agostini, et al., 2013). volume-based incentive spirometry pre- and postoperatively has also been found to improve pulmonary function and diaphragm excursion in patients undergoing laparoscopic surgery (alaparthi, et al., 2016). patients customarily receive an incentive spirometer for use postoperatively in the pacu. there is scant data in the thoracic surgery population concerning prehabilitation by dispensing the incentive spirometer at the pact evaluation.


Eligibility criteria:
inclusion criteria: * patients scheduled for thoracic surgery procedures involving one-lung ventilation * open thoracotomy * video-assisted thoracoscopic surgery (vats) * robotic-assisted thoracoscopic surgery (rats) * procedures to include: lung resection for any purpose, esophagectomy, thymectomy * patients undergoing esophagectomy performed by a general surgeon * patients willing and able to independently perform incentive spirometry exclusion criteria: * trauma patients * lung volume reduction surgery (lvrs) * in-patients * patients not undergoing one-lung ventilation * patients undergoing thoracoabdominal aortic aneurysm repair * transhiatal esophagectomy (does not involve one-lung ventilation) * lung transplantation